Age-Related Macular Degeneration

Primary Care - Clinics in Office Practice

Volumn 42, Issue 3, 2015, Pages 377-391

  Mehta, Sonia ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Age related macular degeneration; Dry AMD; Exudative age related macular degeneration; Neovascular age related macular degeneration; Nonexudative age related macular degeneration; Wet AMD

Indexed keywords

AFLIBERCEPT; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; CUPRIC OXIDE; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VERTEPORFIN; XANTHOPHYLL; ZEAXANTHIN; ZINC OXIDE; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; AMSLER CHART; BLURRED VISION; CENTRAL SCOTOMA; COMORBIDITY; COPPER DEFICIENCY; DRUSEN; EARLY DIAGNOSIS; GEOGRAPHIC ATROPHY; HUMAN; INCIDENCE; LASER COAGULATION; LEAFY VEGETABLE; METAMORPHOPSIA; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL LOW VISION AID; PATIENT REFERRAL; PHOTODYNAMIC THERAPY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; REVIEW; SELF CARE; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION; WET MACULAR DEGENERATION; AGED; ANTAGONISTS AND INHIBITORS; DIETARY SUPPLEMENT; MACULAR DEGENERATION; MIDDLE AGED; OPTICAL INSTRUMENTATION; PHOTOCHEMOTHERAPY; PRIMARY HEALTH CARE; PROCEDURES; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DIETARY SUPPLEMENTS; HUMANS; INCIDENCE; LIGHT COAGULATION; MACULAR DEGENERATION; MIDDLE AGED; OPTICAL DEVICES; PHOTOCHEMOTHERAPY; PREVALENCE; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940196557     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2015.05.009     Document Type: Review

References (34)

1. Klein R., Rowland M.L., Harris M.I. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995, 102:371-381.
2. U.S. age-specific prevalence rates for AMD by age, and race/ethnicity. 2010. Available at: . Accessed January 3, 2015. https://nei.nih.gov/eyedata/amd.
3. The Eye Diseases Research Prevalence Research Group The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004, 122:552-563.
4. Seddon J.M. Epidemiology of age-related macular degeneration. Retina 2001, 1039-1050. Mosby, St Louis (MO). 3rd edition. A.P. Schachat, S. Ryan (Eds.).
5. Thornton J., Edwards R., Mitchell P., et al. Smoking and age-related macular degeneration: a review of association. Eye 2005, 19:935-944.
6. Van Leeuwen R., Boekhoom S., Vingerling J.R., et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005, 294:3101-3107.
7. Sui G.Y., Liu G.C., Liu G.Y., et al. Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br J Ophthalmol 2013, 97:389-394.
8. Bhutto I., Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med 2012, 33:295-317.
9. Kozlowski M.R. RPE cell senescence: a key contributor to age-related macular degeneration. Med Hypotheses 2012, 78:505-510.
10. The Age-Related Eye Disease Study Research Group A randomized, placebo controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 2001, 119:1417-1436.
11. Holz F.G., Steinberg J.S., Gobel A., et al. Fundus autofluorescence imaging in dry AMD: 2014 Jules Gonin lecture of the Retina Research Foundation. Graefes Arch Clin Exp Ophthalmol 2015, 253:7-16.
12. Klein R., Klein B.E., Wong T.Y., et al. The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2002, 120:1551-1558.
13. Forooghian F., Argon E., Clemons T.E., Age-Related Eye Disease Study Research Group, et al. Visual acuity outcomes after cataract surgery in patients with age-related macular degeneration: age-related eye disease study report no. 27. Ophthalmology 2009, 116:2093-2100.
14. Tomi A., Moldoveanu A., Marin I. Therapeutic approach in patients with age-related macular degeneration and cataract. Oftalmologia 2011, 55:54-59.
15. Zlateva G.P., Javitt J.C., Shah S.N., et al. Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the Medicare population. Retina 2007, 27:1292-1299.
16. Boyer D.S., Antoszyk A.N., Awh C.C., et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007, 114:246-252.
17. US Preventative Services Task Force Screening for visual impairment. Guide to clinical preventative services 1996, 373-382. Williams & Wilkins, Baltimore (MD). 2nd edition.
18. American Academy of Family Physicians AAFP reference manual: selected policies on health issues, clinical policies, in-house (operational) policies. 1999-2000 1999, 213. The American Academy of Family Physicians, Kansas City (MO).
19. AAO Retina/Vitreous PPP Panel, Hoskins Center for Quality Eye Care. American Academy of Ophthalmology preferred practice patterns for age-related macular degeneration. Available at: . Accessed January 3, 2015. http://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015.
20. AREDS2 Research Group Lutein/zeaxanthin and omega-3 fatty acids for age-related macular degeneration. The Age-Related Eye Disease Study 2 (AREDS2) controlled randomized clinical trial. JAMA 2013, 19:2005-2015.
21. The effects of vitamin E beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994, 330:1029-1035.
22. Grisanti S., Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 2007, 55:417-420.
23. Rosenfeld P.J., Brown D.M., Heier J.S., MARINA Study Group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431.
24. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin D.F., Maguire M.G., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012, 119:1288-1298.
25. Chakravarthy U., Harding S.P., Rogers C.A., IVAN Study Investigators, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2 year findings of the IVAN randomized controlled trial. Lancet 2013, 382:1258-1267.
26. Heier J.S., Brown D.M., Chong V., VIEW Study Group Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012, 119:2537-2548.
27. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F., VIEW Study Group Intravitreal aflibercept injection for neovascular age-related macular degeneration: nine-six week results of the VIEW studies. Ophthalmology 2014, 121:193-201.
28. Macular Photocoagulation Study Group Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994, 112:500-509.
29. Macular Photocoagulation Study Group Laser photocoagulation for subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1993, 111:1200-1209.
30. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999, 117:1329-1345.
31. Seddon J.M., Ajani U.A., Sperduto R.D., Eye Disease Case Control Study Group, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 1994, 272:1413-1420.
32. Wong T., Chakravarthy U., Klein R., et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008, 115:116-126.
33. Faes L., Bodmer N.S., Bachmann L.M., et al. Diagnostic accuracy of the Amsler grid and preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye 2014, 28:788-796.
34. Chew E.Y., Clemons T.E., Bressler S.B., The AREDS2-HOME Study Research Group, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization Home Monitoring of the Eye (HOME) study. Ophthalmology 2014, 121:535-544.